Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00899847 · OUTCOME

Overall Survival (OS)

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG · Source last updated 2017-10-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
2 years after the last participant is enrolled

What was measured

To evaluate the graft versus myeloma effect by monitoring rate of overall survival (OS)

Analysis population: Includes all study participants

Groups in this outcome

Autologous-Allogeneic Hematopoietic Stem Cell Transplant

A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Autologous-Allogeneic Hematopoietic Stem Cell Transplant9

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Autologous-Allogeneic Hematopoietic Stem Cell Transplant67Not reported2887Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        28
        upper Limit
        87
        value
        67
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    units
    Participants
description
To evaluate the graft versus myeloma effect by monitoring rate of overall survival (OS)
dispersion Type
95% Confidence Interval
groups
  1. description
    A high-dose sequential chemotherapy approach with cyclophosphamide and etoposide followed by granulocyte colony stimulating factor (G-CSF) for collection of peripheral blood progenitor cells as well as for cytoreduction. Total Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).The preparatory regimens use BCNU and melphalan.
    id
    OG000
    title
    Autologous-Allogeneic Hematopoietic Stem Cell Transplant
param Type
NUMBER
population Description
Includes all study participants
reporting Status
POSTED
time Frame
2 years after the last participant is enrolled
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice